Apoptosis and cancer: the genesis of a research field

[1]  P. Colman,et al.  BCL-2 family antagonists for cancer therapy , 2008, Nature Reviews Drug Discovery.

[2]  John Calvin Reed,et al.  Bcl-2 family proteins and cancer , 2008, Oncogene.

[3]  Mark J. Smyth,et al.  The TRAIL apoptotic pathway in cancer onset, progression and therapy , 2008, Nature Reviews Cancer.

[4]  A. Letai,et al.  Diagnosing and exploiting cancer's addiction to blocks in apoptosis , 2008, Nature Reviews Cancer.

[5]  Lorenzo Galluzzi,et al.  Mitochondrial membrane permeabilization in cell death. , 2007, Physiological reviews.

[6]  C. Prives,et al.  Transcriptional regulation by p53: one protein, many possibilities , 2006, Cell Death and Differentiation.

[7]  G. Evan,et al.  Specific Requirement for Bax, Not Bak, in Myc-induced Apoptosis and Tumor Suppression in Vivo* , 2006, Journal of Biological Chemistry.

[8]  C. Croce,et al.  miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Korsmeyer,et al.  A Role for Proapoptotic BID in the DNA-Damage Response , 2005, Cell.

[10]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[11]  D. Vaux.  Early work on the function of Bcl-2, an interview with David Vaux , 2004, Cell Death and Differentiation.

[12]  C. Martínez-A,et al.  c-Myc-deficient B lymphocytes are resistant to spontaneous and induced cell death , 2004, Cell Death and Differentiation.

[13]  Govind Bhagat,et al.  Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. , 2003, The Journal of clinical investigation.

[14]  J. Cleveland,et al.  c-Myc Augments Gamma Irradiation-Induced Apoptosis by Suppressing Bcl-XL , 2003, Molecular and Cellular Biology.

[15]  H. Horvitz,et al.  NOBEL LECTURE: Worms, Life and Death , 2003, Bioscience reports.

[16]  S. R. Datta,et al.  Bad-deficient mice develop diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Helen Conroy,et al.  Caspase‐activation pathways in apoptosis and immunity , 2003, Immunological reviews.

[18]  Jenny C. Chang,et al.  Survival of patients with metastatic breast carcinoma , 2003, Cancer.

[19]  L. Frati,et al.  Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Forteza,et al.  Predictive Value of P53, BCL-2, and BAX in Advanced Head and Neck Carcinoma , 2002, American journal of clinical oncology.

[21]  E. Ioachim,et al.  Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer. , 2002, Anticancer research.

[22]  Joanna K. Sax,et al.  BID regulation by p53 contributes to chemosensitivity , 2002, Nature Cell Biology.

[23]  Gail M. Williams,et al.  Apoptosis and Expression of Bcl-2, Bcl-XL, and Bax in Renal Cell Carcinomas , 2002, Cancer investigation.

[24]  J. Cleveland,et al.  Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1 , 2001, Oncogene.

[25]  G. Chalkiadakis,et al.  Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients? , 2001, The Journal of surgical research.

[26]  D. Andrews,et al.  Myc Potentiates Apoptosis by Stimulating Bax Activity at the Mitochondria , 2001, Molecular and Cellular Biology.

[27]  K. Vousden,et al.  PUMA, a novel proapoptotic gene, is induced by p53. , 2001, Molecular cell.

[28]  K. Kinzler,et al.  PUMA induces the rapid apoptosis of colorectal cancer cells. , 2001, Molecular cell.

[29]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.

[30]  Robert L Moritz,et al.  Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins , 2000, Cell.

[31]  T. Taniguchi,et al.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. , 2000, Science.

[32]  A. Strasser,et al.  Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. , 1999, Science.

[33]  D. Felsher,et al.  Reversible tumorigenesis by MYC in hematopoietic lineages. , 1999, Molecular cell.

[34]  G. Evan,et al.  Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. , 1999, Molecular cell.

[35]  John Calvin Reed,et al.  Prognostic significance of apoptosis regulators in breast cancer. , 1999, Endocrine-related cancer.

[36]  D. Israeli,et al.  p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.

[37]  G. Kroemer,et al.  Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. , 1998, Cancer research.

[38]  K. Franssila,et al.  A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer. , 1998, British Journal of Cancer.

[39]  A. Strasser,et al.  Bim: a novel member of the Bcl‐2 family that promotes apoptosis , 1998, The EMBO journal.

[40]  S. Nagata,et al.  A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD , 1998, Nature.

[41]  P. Galle,et al.  CD95(APO-1/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells. , 1998, Advances in cancer research.

[42]  K. Franssila,et al.  BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. , 1997, Blood.

[43]  J C Reed,et al.  Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Blood.

[44]  D. Cunningham,et al.  BCL-2 antisense therapy in patients with non-Hodgkin lymphoma , 1997, The Lancet.

[45]  D. Vaux,et al.  Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Dean P. Jones,et al.  Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked , 1997, Science.

[47]  P. Galle,et al.  Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. , 1997, The Journal of clinical investigation.

[48]  P. Galle,et al.  Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion? , 1996, Nature Medicine.

[49]  J. Tschopp,et al.  Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.

[50]  C. Milliman,et al.  BID: a novel BH3 domain-only death agonist. , 1996, Genes & development.

[51]  N. Copeland,et al.  bcl-w, a novel member of the bcl-2 family, promotes cell survival. , 1996, Oncogene.

[52]  Xiaodong Wang,et al.  Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c , 1996, Cell.

[53]  S. Marsters,et al.  Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family* , 1996, The Journal of Biological Chemistry.

[54]  I. Herr,et al.  Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells , 1996, Nature Medicine.

[55]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[56]  D. Green,et al.  Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege , 1995, Science.

[57]  D. Bellgrau,et al.  A role for CD95 ligand in preventing graft rejection , 1995, Nature.

[58]  K. Franssila,et al.  Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. , 1995, Cancer research.

[59]  G. Evan,et al.  Induction of apoptosis by the Bcl-2 homologue Bak , 1995, Nature.

[60]  B. Dörken,et al.  Expression of the bcl‐2 gene family in normal and malignant breast tissue: Low bax‐α expression in tumor cells correlates with resistance towards apoptosis , 1995, International journal of cancer.

[61]  D. Thorley-Lawson,et al.  A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.

[62]  S. Korsmeyer,et al.  Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces bax and promotes cell death , 1995, Cell.

[63]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[64]  P. O'Connor,et al.  Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. , 1994, Oncogene.

[65]  John Calvin Reed,et al.  Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. , 1994, Oncogene.

[66]  M. Seto,et al.  Loss of Heterozygosity at the bcl‐2 Gene Locus and Expression of bcl‐2 in Human Gastric and Colorectal Carcinomas , 1994, Japanese journal of cancer research : Gann.

[67]  C. Winterford,et al.  Apoptosis. Its significance in cancer and cancer Therapy , 1994, Cancer.

[68]  D. Green,et al.  BCR-ABL Maintains Resistance of Chronic Myelogenous Leukemia Cells to Apoptotic Cell Death , 1994 .

[69]  T G Cotter,et al.  BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. , 1994, Blood.

[70]  J. Minna,et al.  Expression of bcl-2 in small cell lung carcinoma cells. , 1994, Cancer research.

[71]  Takashi Suda,et al.  Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor family , 1993, Cell.

[72]  G. Núñez,et al.  Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. , 1993, The American journal of pathology.

[73]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[74]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[75]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[76]  S. Nagata,et al.  Lethal effect of the anti-Fas antibody in mice , 1993, Nature.

[77]  R. Craig,et al.  MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[78]  John Calvin Reed,et al.  bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. , 1993, Blood.

[79]  D. Green,et al.  Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. , 1992, Science.

[80]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[81]  S. Korsmeyer,et al.  bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes , 1991, Cell.

[82]  Y. Chen,et al.  Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate. , 1991, Oncogene.

[83]  J. Cleveland,et al.  Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. , 1991, Oncogene.

[84]  Atsushi Hase,et al.  The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis , 1991, Cell.

[85]  A. Kimchi,et al.  Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.

[86]  T. Crompton.  IL3-dependent cells die by apoptosis on removal of their growth factor. , 1991, Growth factors.

[87]  R. Schreiber,et al.  Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.

[88]  A. Strasser,et al.  Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2 , 1990, Nature.

[89]  J C Reed,et al.  Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. , 1990, Cancer research.

[90]  M. Collins,et al.  Regulation of apoptosis in interleukin‐3‐dependent hemopoietic cells by interleukin‐3 and calcium ionophores. , 1990, The EMBO journal.

[91]  T. Dexter,et al.  Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis , 1990, Nature.

[92]  Y. Tsujimoto.  Stress-resistance conferred by high level of bcl-2 alpha protein in human B lymphoblastoid cell. , 1989, Oncogene.

[93]  P. Möller,et al.  Monoclonal antibody-mediated tumor regression by induction of apoptosis. , 1989, Science.

[94]  S. Yonehara,et al.  A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor , 1989, The Journal of experimental medicine.

[95]  S. Korsmeyer,et al.  bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation , 1989, Cell.

[96]  P. Nowell,et al.  Oncogenic potential of bcl-2 demonstrated by gene transfer , 1988, Nature.

[97]  David L. Vaux,et al.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.

[98]  J. Sklar,et al.  Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation , 1986, Cell.

[99]  Y. Tsujimoto,et al.  Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[100]  P. Nowell,et al.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. , 1984, Science.

[101]  A. Wyllie.  Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation , 1980, Nature.

[102]  A. Wyllie,et al.  Cell death: the significance of apoptosis. , 1980, International review of cytology.

[103]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[104]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[105]  J. W. Saunders,et al.  Death in Embryonic Systems , 1966, Science.

[106]  J. Kerr,et al.  A histochemical study of hypertrophy and ischaemic injury of rat liver with special reference to changes in lysosomes. , 1965, The Journal of pathology and bacteriology.

[107]  R. Lockshin,et al.  PROGRAMMED CELL DEATH--I. CYTOLOGY OF DEGENERATION IN THE INTERSEGMENTAL MUSCLES OF THE PERNYI SILKMOTH. , 1965, Journal of insect physiology.

[108]  A. Glücksmann.  CELL DEATHS IN NORMAL VERTEBRATE ONTOGENY , 1951 .